Dharushana Muthulingam1, Joshua Bia2, Lynn M Madden3, Scott O Farnum3, Declan T Barry4, Frederick L Altice5. 1. Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA. Electronic address: dharushana.muthulingam@yale.edu. 2. Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, USA. 3. Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA; APT Foundation, Inc, New Haven, CT, USA. 4. APT Foundation, Inc, New Haven, CT, USA; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. 5. Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA; APT Foundation, Inc, New Haven, CT, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND: The opioid crisis requires rapid scale-up of evidence-based interventions to treat opioid use disorder (OUD), of which pharmacologic therapies with methadone, buprenorphine or long-acting naltrexone are most effective. With recently-developed formulations, there are unprecedented treatment options. Even when pharmacologic treatment is accessible, however, uptake remains low, suggesting individual-level barriers. Decision aids are an evidence-based strategy that may overcome these barriers. This study aims to inform such a tool by describing and rank-ordering patients' considerations when deciding whether to start medication and, if starting, choosing a medication. METHODS: Adults with OUD (N = 81) attending an addiction treatment center or syringe exchange program completed focus groups using nominal group technique, a consensus method that generates and ranks response. The qualitative component generates a broad array of responses, followed by rank-ordering to prioritize responses. Responses to questions about starting any medications and the pros and cons of five specific medications were ranked and coded. RESULTS: The decision to initiate pharmacologic therapy and choose among medications was influenced by six key attributes in decreasing priority: (1) benefits, (2) side effects of treatment, (3) medication delivery strategies, (4) convenience, (5) how expectations for treatment are met, and (6) how medication (especially methadone) can represents trading one addiction for another. CONCLUSIONS: Pharmacologic properties, logistical factors, and managing expectations were important themes in decision-making for starting, choosing, and staying on medications, and to a lesser degree, negative views about medications, specifically OAT, as an addiction itself. Desire for more control over treatment persisted in all themes. This study identified specific knowledge gaps, expectations, and priorities which are important for developing a decision aid for OUD treatment relevant to the target group. Nominal group technique is an established mixed-methodology that we have applied to a new population and purpose, that of conducting needs assessment for decision aid development.
BACKGROUND: The opioid crisis requires rapid scale-up of evidence-based interventions to treat opioid use disorder (OUD), of which pharmacologic therapies with methadone, buprenorphine or long-acting naltrexone are most effective. With recently-developed formulations, there are unprecedented treatment options. Even when pharmacologic treatment is accessible, however, uptake remains low, suggesting individual-level barriers. Decision aids are an evidence-based strategy that may overcome these barriers. This study aims to inform such a tool by describing and rank-ordering patients' considerations when deciding whether to start medication and, if starting, choosing a medication. METHODS: Adults with OUD (N = 81) attending an addiction treatment center or syringe exchange program completed focus groups using nominal group technique, a consensus method that generates and ranks response. The qualitative component generates a broad array of responses, followed by rank-ordering to prioritize responses. Responses to questions about starting any medications and the pros and cons of five specific medications were ranked and coded. RESULTS: The decision to initiate pharmacologic therapy and choose among medications was influenced by six key attributes in decreasing priority: (1) benefits, (2) side effects of treatment, (3) medication delivery strategies, (4) convenience, (5) how expectations for treatment are met, and (6) how medication (especially methadone) can represents trading one addiction for another. CONCLUSIONS: Pharmacologic properties, logistical factors, and managing expectations were important themes in decision-making for starting, choosing, and staying on medications, and to a lesser degree, negative views about medications, specifically OAT, as an addiction itself. Desire for more control over treatment persisted in all themes. This study identified specific knowledge gaps, expectations, and priorities which are important for developing a decision aid for OUD treatment relevant to the target group. Nominal group technique is an established mixed-methodology that we have applied to a new population and purpose, that of conducting needs assessment for decision aid development.
Authors: Glyn Elwyn; Annette O'Connor; Dawn Stacey; Robert Volk; Adrian Edwards; Angela Coulter; Richard Thomson; Alexandra Barratt; Michael Barry; Steven Bernstein; Phyllis Butow; Aileen Clarke; Vikki Entwistle; Deb Feldman-Stewart; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Nora Moumjid; Al Mulley; Cornelia Ruland; Karen Sepucha; Alan Sykes; Tim Whelan Journal: BMJ Date: 2006-08-14
Authors: Deb Feldman-Stewart; Sarah Brennenstuhl; Kathryn McIssac; Joan Austoker; Agathe Charvet; Paul Hewitson; Karen R Sepucha; Tim Whelan Journal: Health Expect Date: 2007-03 Impact factor: 3.377
Authors: Theresa W Kim; Daniel P Alford; Alan Malabanan; Michael F Holick; Jeffrey H Samet Journal: Drug Alcohol Depend Date: 2006-07-21 Impact factor: 4.492
Authors: Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Shannon Gwin Mitchell; James A Peterson; Heather Schacht Reisinger; Michael H Agar; Barry S Brown Journal: Am J Addict Date: 2008 Sep-Oct
Authors: Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch Journal: J Subst Abuse Treat Date: 2020-01-21
Authors: Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2020-06-24 Impact factor: 5.128
Authors: Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128
Authors: Amanda R Liberman; Daniel J Bromberg; Lyuba Azbel; Julia Rozanova; Lynn Madden; Jaimie P Meyer; Frederick L Altice Journal: Int J Drug Policy Date: 2021-04-07
Authors: Kirsten Marchand; Scott Beaumont; Jordan Westfall; Scott MacDonald; Scott Harrison; David C Marsh; Martin T Schechter; Eugenia Oviedo-Joekes Journal: Subst Abuse Treat Prev Policy Date: 2019-09-11
Authors: Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch Journal: Addict Sci Clin Pract Date: 2021-01-27
Authors: Alice Fiddian-Green; Aline Gubrium; Calla Harrington; Elizabeth A Evans Journal: Int J Environ Res Public Health Date: 2022-07-30 Impact factor: 4.614